Terms: = Breast cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Clinical Outcome
50 results:
1. pd-l1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer.
Wang L; Guo W; Guo Z; Yu J; Tan J; Simons DL; Hu K; Liu X; Zhou Q; Zheng Y; Colt EA; Yim J; Waisman J; Lee PP
Cell Rep Med; 2024 Feb; 5(2):101420. PubMed ID: 38382468
[TBL] [Abstract] [Full Text] [Related]
2. TJP3 promotes T cell immunity escape and chemoresistance in breast cancer: a comprehensive analysis of anoikis-based prognosis prediction and drug sensitivity stratification.
Chaojun L; Pengping L; Yanjun L; Fangyuan Z; Yaning H; Yingbo S; Qi C; Hui L
Aging (Albany NY); 2023 Nov; 15(22):12890-12906. PubMed ID: 37950731
[TBL] [Abstract] [Full Text] [Related]
3. Clinicopathological and prognostic value of TIL and PD L1 in triple negative breast carcinomas.
Uğurluoğlu C; Yormaz S
Pathol Res Pract; 2023 Oct; 250():154828. PubMed ID: 37778126
[TBL] [Abstract] [Full Text] [Related]
4. Neoadjuvant Immunotherapy in Early, Triple-Negative breast cancers: Catching Up with the Rest.
Kim L; Coman M; Pusztai L; Park TS
Ann Surg Oncol; 2023 Oct; 30(11):6441-6449. PubMed ID: 37349612
[TBL] [Abstract] [Full Text] [Related]
5. Early changes in soluble intracellular adhesion molecule-1 as prognostic biomarkers to immune checkpoint inhibitor.
Ji D; Jiang S; Zhang Q; Wang YK; Zhang J; Shen W; Li W; Liu R; Wang J; Mavis C; Gu JJ; Hu X
Clin Transl Sci; 2023 Aug; 16(8):1396-1407. PubMed ID: 37317057
[TBL] [Abstract] [Full Text] [Related]
6. High PD-L2 Predicts Early Recurrence of ER-Positive breast cancer.
Chervoneva I; Peck AR; Sun Y; Yi M; Udhane SS; Langenheim JF; Girondo MA; Jorns JM; Chaudhary LN; Kamaraju S; Bergom C; Flister MJ; Hooke JA; Kovatich AJ; Shriver CD; Hu H; Palazzo JP; Bibbo M; Hyslop T; Nevalainen MT; Pestell RG; Fuchs SY; Mitchell EP; Rui H
JCO Precis Oncol; 2023 Jan; 7():e2100498. PubMed ID: 36652667
[TBL] [Abstract] [Full Text] [Related]
7. Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer.
Boissière-Michot F; Chateau MC; Thézenas S; Guiu S; Bobrie A; Jacot W
Front Immunol; 2022; 13():1058424. PubMed ID: 36544779
[TBL] [Abstract] [Full Text] [Related]
8. Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of γH2AX, pRPA2, P53, pd-l1 and tumor infiltrating lymphocytes in 76 cases.
Voutilainen S; Heikkilä P; Bartkova J; Nevanlinna H; Blomqvist C; Bartek J; Mattson J
BMC Cancer; 2022 Dec; 22(1):1298. PubMed ID: 36503417
[TBL] [Abstract] [Full Text] [Related]
9. Expression of HLA class I is associated with immune cell infiltration and patient outcome in breast cancer.
Han SH; Kim M; Chung YR; Woo JW; Choi HY; Park SY
Sci Rep; 2022 Nov; 12(1):20367. PubMed ID: 36437379
[TBL] [Abstract] [Full Text] [Related]
10. Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression.
Giannoudis A; Varešlija D; Sharma V; Zakaria R; Platt-Higgins A; Rudland PS; Jenkinson MD; Young LS; Palmieri C
ESMO Open; 2022 Dec; 7(6):100636. PubMed ID: 36423363
[TBL] [Abstract] [Full Text] [Related]
11. Spatial and Quantitative Analysis of Tumor-Associated Macrophages: Intratumoral CD163-/pd-l1+ TAMs as a Marker of Favorable clinical outcomes in Triple-Negative breast cancer.
Shinohara H; Kobayashi M; Hayashi K; Nogawa D; Asakawa A; Ohata Y; Kubota K; Takahashi H; Yamada M; Tokunaga M; Kinugasa Y; Oda G; Nakagawa T; Onishi I; Kinowaki Y; Kurata M; Ohashi K; Kitagawa M; Yamamoto K
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362023
[TBL] [Abstract] [Full Text] [Related]
12. Essential Roles of TDO2 in Gastric cancer: TDO2 Is Associated with cancer Progression, Patient Survival, pd-l1 Expression, and cancer Stem Cells.
Pham QT; Taniyama D; Akabane S; Takashima T; Maruyama R; Sekino Y; Sentani K; Yasui W; Oue N
Pathobiology; 2023; 90(1):44-55. PubMed ID: 35679834
[TBL] [Abstract] [Full Text] [Related]
13. Adoptive Transfer of Anti-Nucleolin T Cells Combined with pd-l1 Inhibition against Triple-Negative breast cancer.
Thongchot S; Jirapongwattana N; Luangwattananun P; Chiraphapphaiboon W; Chuangchot N; Sa-Nguanraksa D; O-Charoenrat P; Thuwajit P; Yenchitsomanus PT; Thuwajit C
Mol Cancer Ther; 2022 May; 21(5):727-739. PubMed ID: 35313339
[TBL] [Abstract] [Full Text] [Related]
14. Evaluation of pd-l1 Expression in Undifferentiated Pleomorphic Sarcomas, Liposarcomas and Chondrosarcomas.
Zhang Y; Chen Y; Papakonstantinou A; Tsagkozis P; Linder-Stragliotto C; Haglund F
Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204793
[TBL] [Abstract] [Full Text] [Related]
15. Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 update.
Brown LC; Loi S
Breast; 2022 Mar; 62 Suppl 1(Suppl 1):S29-S33. PubMed ID: 34996667
[TBL] [Abstract] [Full Text] [Related]
16. outcome of patients with metastatic triple negative breast cancer treated with first-line chemotherapy: a single institution retrospective analysis.
Bianco N; Milano M; Pagan E; Oriecuia C; Bagnardi V; Rocco EG; Santomauro GI; Peruzzotti G; Colleoni M; Viale G
Breast Cancer Res Treat; 2022 Jan; 191(1):137-145. PubMed ID: 34609640
[TBL] [Abstract] [Full Text] [Related]
17. A single-cell and spatially resolved atlas of human breast cancers.
Wu SZ; Al-Eryani G; Roden DL; Junankar S; Harvey K; Andersson A; Thennavan A; Wang C; Torpy JR; Bartonicek N; Wang T; Larsson L; Kaczorowski D; Weisenfeld NI; Uytingco CR; Chew JG; Bent ZW; Chan CL; Gnanasambandapillai V; Dutertre CA; Gluch L; Hui MN; Beith J; Parker A; Robbins E; Segara D; Cooper C; Mak C; Chan B; Warrier S; Ginhoux F; Millar E; Powell JE; Williams SR; Liu XS; O'Toole S; Lim E; Lundeberg J; Perou CM; Swarbrick A
Nat Genet; 2021 Sep; 53(9):1334-1347. PubMed ID: 34493872
[TBL] [Abstract] [Full Text] [Related]
18. Oncogene-specific differences in tumor mutational burden, pd-l1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract] [Full Text] [Related]
19. Effect of Primary Systemic Therapy on PD-1, pd-l1, and PD-L2 mRNA Expression in Advanced breast cancer.
Karsono R; Azhar MA; Pratiwi Y; Saputra F; Nadliroh S; Aryandono T
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2069-2077. PubMed ID: 34319029
[TBL] [Abstract] [Full Text] [Related]
20. Clinicopathologic Characteristics and clinical outcome of Localized Liposarcoma: A Single-Center Experience over 25 Years and Evaluation of pd-l1 Expression.
Chae H; Kim JE; Kim W; Lee JS; Song SY; Lee MH; Chung HW; Cho KJ; Song JS; Ahn JH
Cancer Res Treat; 2022 Apr; 54(2):579-589. PubMed ID: 34237209
[TBL] [Abstract] [Full Text] [Related]
[Next]
